Over 70% of Vitiligo Patients Desire Skin Repigmentation; New Topical Therapy Introduced in Hong Kong Shows Encouraging Results
HONG KONG SAR – Media OutReach Newswire – 22 June 2025 – In observance of World Vitiligo Day (June 25), Hong Kong Vitiligo Support Group has released findings from its latest “Hong Kong Vitiligo Patients and Caregivers Survey.” The study reveals critical gaps in treatment knowledge, with over 80% of respondents demonstrating limited understanding of available therapies and their efficacy. More than 70% of patients hoped therapy could partially or fully restore their original skin pigmentation, yet many reported disappointing outcomes with existing treatments, leading to loss of confidence and treatment discontinuation.
(From
left)
Mr.
Chan
(pseudonym),
a
patient
with
vitiligo;
Dr.
Chan
Yung,
a
specialist
in
dermatology;
and
Ms.
Amy
Wong,
a
registered
social
worker
from
the
Hong
Kong
Vitiligo
Support
Group,
urge
individuals
with
vitiligo
to
seek
professional
medical
consultation
for
personalized
treatment
plan
promptly
and
to
avoid
unproven
remedies
Dr.
Chan
Yung,
a
specialist
in
dermatology,
noted
that
with
advancing
insights
into
vitiligo
pathogenesis,
novel
therapy
has
recently
been
introduced
in
Hong
Kong.
Clinical
studies
confirm
its
repigmentation
potential,
encouraging
patients
to
consult
specialists
for
personalized
treatment
plans.
In Hong Kong, vitiligo affects approximately 1% of the population, with an estimated 70,000 individuals living with the condition. In May 2025, Hong Kong Vitiligo Support Group successfully surveyed 61 patients or their primary caregivers to identify key challenges in disease management. Key findings as follows:
1.
Critical
Knowledge
Deficits
in
Treatment
Understanding
- 80% lack understanding of treatment options
- 78% unfamiliar with medication efficacy
- 84% uncertain about which specialist to consult
- 74% of respondents expressed a desire for full or partial skin repigmentation, yet among the 48 treated patients, none achieved complete repigmentation, and only 8% reported partial improvement
- 67% perceived treatments as completely ineffective
- 43% are not receiving any active treatment at present
- Barriers included: high private healthcare costs and long public-sector wait times (95%), and perceived futility of therapy (75%)
-
Corticosteroids:
Risk
of
skin
atrophy,
telangiectasia;
unsuitable
for
long-term
use
-
Phototherapy:
Requires
3–6
months
(or
longer)
of
2–3
weekly
sessions,
with
potential
sunburn
and
skin
cancer
risks
-
Non-steroidal
topicals:
Often
only
slow
progression
rather
than
induce
repigmentation
Over 70% of Vitiligo Patients Seek Skin Repigmentation – New Topical Treatment Introduced in Hong Kong Offers Hope
Dr. Chan Yung stated that targeted therapies like topical JAK inhibitors represent a breakthrough in vitiligo treatment. “Topical JAK inhibitors are non-steroidal medications with demonstrated efficacy and safety profiles, making them a viable long-term treatment option for patients,” he explained.
While the exact etiology of vitiligo remains unclear, current evidence suggests autoimmune-mediated attack on melanocytes plays a key pathogenic role, resulting in depigmented lesions. Non-steroidal Topical JAK inhibitors work by modulating the aberrant immune signaling responsible for melanocyte attack, enabling gradual repigmentation of affected areas.
Ruxolitinib
cream,
the
first
FDA-approved
non-steroidal
topical
JAK
inhibitor
for
localized
treatment
of
non-segmental
vitiligo
in
patients
aged
12
years
and
above,
has
recently
become
available
in
Hong
Kong.
Clinical
trials
show:
-
Approximately
30%
of
patients
achieved
≥75%
improvement
in
Facial
Vitiligo
Area
Scoring
Index
(F-VASI)
after
24
weeks
of
treatment;
-
50%
of
patients
showed
≥50%
improvement;
-
Extension
to
52
weeks
of
treatment
resulted
in
>50%
of
patients
attaining
≥75%
improvement7
Ms. Amy Wong, a Registered Social Worker at Hong Kong Vitiligo Support Group noted that many vitiligo patients and caregivers seeking assistance express confusion about treatment options and medication efficacy. “Many patients spend over a year just obtaining a definitive diagnosis,” she explained. “In their search for solutions, patients often invest substantial resources in various cosmetic packages and alternative therapies, only to experience significant discrepancies between desired and actual outcomes. This frequently leads to disillusionment, loss of hope for effective treatment, and even emotional distress.”
“However,” Ms. Wong emphasized, “with medical advancements, vitiligo is no longer considered untreatable. Repigmentation is now achievable, and we strongly encourage patients to seek professional medical consultation at the earliest opportunity.”
Conclusion and Recommendations
The survey reveals significant gaps in patients’ understanding of vitiligo treatments and their mechanisms, leaving many uncertain about where to begin treatment. Over 80% of respondents expressed desire for patient support in medication access and resource referrals. Accordingly, Dr. Chan Yung and Ms. Amy Wong, propose the following recommendations:
1.
Public
Education
Seminars
Conduct
lectures
and
workshops
to
help
patients
and
caregivers
understand
that
vitiligo
requires
long-term
management,
with
visible
results
often
taking
extended
periods
to
manifest.
These
initiatives
should
also
educate
participants
about
various
treatment
modalities,
particularly
newly
available
options
like
non-steroidal
topical
JAK
inhibitors,
enabling
informed
discussions
with
healthcare
providers
about
appropriate
treatment
plans.
2.
Medication
Support
and
Resource
Referral
Services
Given
that
vitiligo
necessitates
prolonged
treatment,
and
considering
that
many
patients
find
private
care
cost-prohibitive
while
public
service
wait
times
are
excessively
long,
we
recommend
establishing
medication
support
and
resource
referral
services
to
facilitate
timely
access
to
proper
treatment.
Hong
Kong
Vitiligo
Support
Group
is
currently
implementing
a
“Vitiligo
Patient
Support
Program,”
offering
free
psychological
counseling,
medication
assistance,
and
resource
referral
services.
Interested
individuals
may
contact
Hong
Kong
Vitiligo
Support
Group
for
details.
Case Study
Mr. Chan (pseudonym), 58, first developed symptoms thirty years ago with a small depigmented spot on his neck that subsequently spread to his neck, waist, wrists, and thighs. At diagnosis, his physician prescribed topical corticosteroids but stated vitiligo was essentially “incurable.” Mr. Chan subsequently pursued numerous alternative treatments including UV light therapy, traditional Chinese medicine, electroacupuncture, topical shampoo applications, and cosmetic packages – exhausting savings and liquidating his stocks – all without achieving satisfactory repigmentation.
After years of unsuccessful treatment attempts, he discontinued treatment until being referred to the Hong Kong Vitiligo Support Group. Through their seminars and “Vitiligo Patient Support Program”, he learned about modern treatment advances and, with medication assistance, has begun new therapy with renewed hope for repigmentation.
“My greatest wish is to wear crew-neck shirts again,” Mr. Chan shared. “Since developing vitiligo, I’ve only worn high-collared shirts to conceal neck patches and haven’t gone swimming in thirty years.” He looks forward to regaining sartorial freedom following successful repigmentation.
https://hkvsg.org/
Hashtag: #Vitiligo #WorldVitiligoDay #TopicalJAKinhibitors #Non-steroidalTopicalJAKinhibitors #Ruxolitinibcream #SkinRepigmentation #Dr.ChanYung #Dermatology #Skincare#HongKongVitiligoSupportGroup
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate